MARKET

SNTI

SNTI

Senti Bioscience
NASDAQ
0.8320
+0.0219
+2.70%
After Hours: 0.8292 -0.0028 -0.34% 18:54 02/13 EST
OPEN
0.8203
PREV CLOSE
0.8101
HIGH
0.8725
LOW
0.8174
VOLUME
118.37K
TURNOVER
--
52 WEEK HIGH
5.10
52 WEEK LOW
0.7970
MARKET CAP
21.87M
P/E (TTM)
-0.2975
1D
5D
1M
3M
1Y
5Y
1D
Senti Bio completes enrollment in Phase 1 trial of SENTI-202
TipRanks · 2d ago
Senti Biosciences Completes Enrollment In Phase 1 Clinical Trial Evaluating SENTI-202, CD33/FLT3-Targeting Logic Gated CAR NK Cell Therapy, In Patients With R/R AML
Benzinga · 2d ago
Senti Biosciences Completes Phase 1 Enrollment for SENTI-202 in Relapsed or Refractory AML
Reuters · 2d ago
SENTI BIOSCIENCES COMPLETES ENROLLMENT IN PHASE 1 CLINICAL TRIAL OF SENTI-202 FOR THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)
Reuters · 2d ago
Weekly Report: what happened at SNTI last week (0202-0206)?
Weekly Report · 4d ago
Senti Biosciences to Present Gene Circuit Platform at Healthcare Conference Taipei
Reuters · 02/03 14:00
Weekly Report: what happened at SNTI last week (0126-0130)?
Weekly Report · 02/02 09:25
Weekly Report: what happened at SNTI last week (0119-0123)?
Weekly Report · 01/26 09:25
More
About SNTI
Senti Biosciences, Inc. and its subsidiaries is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The Company is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.

Webull offers Senti Biosciences Inc stock information, including NASDAQ: SNTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNTI stock methods without spending real money on the virtual paper trading platform.